SIGNIFICANT ITCH REDUCTION WITH OPZELURA1,2

4-POINT IMPROVEMENT IN ITCH (ITCH NRS4*) AT WEEK 81-3

Line chart shows the percentage of patients who achieved Itch NRS4 by week 8 of the TRuE-AD1 and TRuE-AD2 clinical trials: 52.2% with OPZELURA vs 15.4% with vehicle and 50.7% with OPZELURA vs 16.3% with vehicle, respectively; P<0.0001.
Line chart shows the percentage of patients who achieved Itch NRS4 by week 8 of the TRuE-AD1 and TRuE-AD2 clinical trials: 52.2% with OPZELURA vs 15.4% with vehicle and 50.7% with OPZELURA vs 16.3% with vehicle, respectively; P<0.0001.

Adapted from Papp K et al. doi:10.17632/ffx6nd5zyb.1. Licensed under CC BY 4.0.

>50% of patients

achieved a clinically meaningful improvement in itch at week 81,2*

  • Itch NRS4 response seen as early as day 3
    (18.4% vs 4.2% and 13.2% vs 0% vehicle)4

*Itch NRS4 is defined as the achievement of at least a 4-point improvement in daily itch on a
0- to 10-point scale, considered a clinically meaningful response; patients in the analysis had an NRS score ≥4 at baseline.1,2

In TRuE-AD1 and TRuE-AD2 respectively.1,2

BID=twice daily; EASI=Eczema Area and Severity Index; NRS=numeric rating scale.

Patient Isabelle

CHANGE IN ITCH NRS THROUGH WEEK 82

Line chart shows the daily mean change from baseline in Itch NRS score up to day 56 of the TRuE-AD1 and TRuE-AD2 clinical trials.
Line chart shows the daily mean change from baseline in Itch NRS score up to day 56 of the TRuE-AD1 and TRuE-AD2 clinical trials.

Adapted with permission from Papp K et al. J Am Acad Dermatol. doi:10.1016/j.jaad.2021.04.085.

ADDITIONAL EXPLORATORY
ANALYSIS
ADDITIONALEXPLORATORY ANALYSIS
Patient-reported change in Itch NRS score observed as early as day 1 and through day 562
Patient- reported change in Itch NRS score observed as early as day 1 and through day 562
Patient Isabelle

Results were not adjusted for multiple comparisons.

BID=twice daily; EASI=Eczema Area and Severity Index; NRS=numeric rating scale.

Patient Isabelle

See EASI results >

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized,
double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085. 3. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 4. Data on file. Incyte Corporation. 2021.